Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 55
Filter
Add more filters










Publication year range
1.
Pediatrics ; 107(5): E65, 2001 May.
Article in English | MEDLINE | ID: mdl-11331715

ABSTRACT

After having made decisions about college, medical school, and specialty training, some residents may delay consideration of their future career in pediatrics. Others, having decided what path they will pursue, are not clear as to what steps need to be taken to ensure that they approach their choice armed with the most appropriate and accurate information. Residents seek career choice information from various sources. For many, the resources may not be able to provide as complete information in all facets of career decision-making. An Internet accessible site for career planning for pediatric residents has been developed (). The advantages, beyond ease of access by all residents, are many, particularly the power of links to other Internet resources. In addition, a website provides the ability to rapidly update and add information, which is not feasible in printed form. career planning, pediatric residents, jobs, private practice, pediatric specialties.


Subject(s)
Career Choice , Employment , Pediatrics , Directories as Topic , Internet , Internship and Residency , United States
3.
Pediatrics ; 106(5): 1199-223, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11073552

ABSTRACT

The Future of Pediatric Education II (FOPE II) Project was a 3-year, grant-funded initiative, which continued the work begun by the 1978 Task Force on the Future of Pediatric Education. Its primary goal was to proactively provide direction for pediatric education for the 21st century. To achieve this goal, 5 topic-specific workgroups were formed: 1) the Pediatric Generalists of the Future Workgroup, 2) the Pediatric Specialists of the Future Workgroup, 3) the Pediatric Workforce Workgroup, 4) the Financing of Pediatric Education Workgroup, and 5) the Education of the Pediatrician Workgroup. The FOPE II Final Report was recently published as a supplement to Pediatrics (The Future of Pediatric Education II: organizing pediatric education to meet the needs of infants, children, adolescents, and young adults in the 21st century. Pediatrics. 2000;105(suppl):161-212). It is also available on the project web site at: This report reflects the deliberations and recommendations of the Pediatric Generalists of the Future Workgroup of the Task Force on FOPE II. The report looks at 5 factors that have led to changes in child health needs and pediatric practice over the last 2 decades. The report then presents a vision for the role and scope of the pediatrician of the future and the core attributes, skills, and competencies pediatricians caring for infants, children, adolescents, and young adults will need in the 21st century. Pediatrics 2000;106(suppl):1199-1223; pediatrics, medical education, children, adolescents, health care delivery.


Subject(s)
Education, Medical/standards , Pediatrics/education , Adolescent , Child , Child, Preschool , Education, Medical/methods , Education, Medical/trends , Humans , Infant , Pediatrics/trends , United States
4.
Pediatr Clin North Am ; 43(3): 599-622, 1996 Jun.
Article in English | MEDLINE | ID: mdl-8649901

ABSTRACT

The authors' impression is that the CBC provides much more information than is routinely used. When anemia is present, the CBC contains considerable information regarding its cause, which can assist in formulating a differential diagnosis and directing further evaluation. White blood cell and platelet count levels may similarly direct practitioners to consider or dismiss underlying conditions. This article assists the pediatrician in optimizing use of this familiar diagnostic tool.


Subject(s)
Blood Cell Count , Anemia, Macrocytic/diagnosis , Anemia, Neonatal/diagnosis , Humans , Infant , Infant, Newborn , Platelet Count , Reticulocyte Count , Thrombocytopenia/diagnosis , Thrombocytosis/diagnosis
5.
J Pediatr ; 126(3): 395-7, 1995 Mar.
Article in English | MEDLINE | ID: mdl-7869200

ABSTRACT

We describe two children who had breath-holding spells that were accelerating in frequency and severity and in one case had recrudesced. Both patients had signs, symptoms, and laboratory findings of severe anemia. With correction of anemia the breath-holding spells promptly and completely resolved in each case. We conclude that in some patients anemia may be a factor contributing to breath-holding spells and that correction of concomitant anemia may produce amelioration or remission of the spells.


Subject(s)
Anemia, Iron-Deficiency/complications , Apnea/etiology , Child Behavior , Anemia, Iron-Deficiency/therapy , Child, Preschool , Female , Humans , Infant , Respiration
9.
NIDA Res Monogr ; 61: 35-49, 1985.
Article in English | MEDLINE | ID: mdl-3932880

ABSTRACT

The National Survey provides us with a number of realities about cocaine use in the Nation today: Twenty million or more Americans have now tried it, and half of that number are past-year users. Cocaine use tends to be concentrated in the high-risk 18 to 25 population group. The highest prevalence rates are observed in young white males, in young residents of the West and the Northeast, and among white and college-educated young people. The young adult cocaine user is likely to consume this drug occasionally and to be a more frequent user of alcohol and/or marijuana. It is not unusual for him or her to use marijuana in combination with cocaine. With respect to recent trends, even though dramatic increases in cocaine prevalence among young adults have leveled off, this still means that high levels of cocaine use are being maintained by young Americans. Moreover, small but steady increases in prevalence are continuing for the youth population. And, the overall number of Americans who have used and are using cocaine continues to increase as new cohorts of young persons begin and continue the use of this drug--even as they move into the older age ranges.


Subject(s)
Cocaine , Substance-Related Disorders/epidemiology , Adolescent , Adult , Child , Female , Humans , Male , Marijuana Abuse , Time Factors , United States
10.
Cancer Drug Deliv ; 2(2): 133-8, 1985.
Article in English | MEDLINE | ID: mdl-4052928

ABSTRACT

Dihydrofolate reductase (DHFR), the main target for methotrexate and other antifolate compounds was found to be present in 100-200 times higher concentration in human cell lines grown in vitro than in human tumors or cells obtained in situ. The DHFR content of human cell lines in vitro however were equivalent to rodent tumor lines also measured in vitro. The enzyme was quantitated by [3H]methotrexate binding, [3H]dihydrofolate reduction to [3H]tetrahydrofolate, and immunoprecipitation with a monospecific anti-serum to DHFR. Additional studies revealed only a liver sample to contain significant amounts of an inhibitor of DHFR activity. It is postulated either that low levels of DHFR in fresh human tissue reflect low cell turnover or conversely that high levels in vitro and in animal tissues reflect high levels of enzyme due to selection because of high levels of folic acid in culture medium and prepared feeds.


Subject(s)
Leukemia, Experimental/enzymology , Neoplasms/enzymology , Tetrahydrofolate Dehydrogenase/deficiency , Animals , Cattle , Cell Line , Cells, Cultured , Chickens , Humans , Liver/enzymology , Methotrexate/metabolism , NADP/metabolism , Tissue Distribution
11.
Nature ; 309(5969): 626-8, 1984.
Article in English | MEDLINE | ID: mdl-6728022

ABSTRACT

Mammalian cells selected for resistance to certain cytotoxic drugs frequently develop cross-resistance to a broad spectrum of other drugs unrelated in structure to the original selective agent. This phenomenon constitutes a major problem in cancer chemotherapy. Multi-drug resistance arises from decreased intracellular drug accumulation, apparently due to an alteration of the plasma membrane. The observation of double minute chromosomes or homogeneously staining regions in some of the multi-drug-resistant cell lines suggests that gene amplification underlies this phenomenon. We have used the technique of DNA renaturation in agarose gels to detect, compare and clone amplified DNA sequences in Adriamycin- and colchicine-resistant sublines of Chinese hamster cells. We show that both Adriamycin- and colchicine-resistant cells contain amplified DNA fragments, some of which are amplified in both of these independently derived cell lines. Furthermore, loss of the multi-drug resistance phenotype on growth in the absence of drugs correlates with the loss of amplified DNA. These results strongly suggest that the DNA sequences which are amplified in common in multi-drug-resistant cell lines include the gene(s) responsible for a common mechanism of multi-drug resistance in these cells. We have cloned one of the commonly amplified DNA fragments and show that the degree of amplification of this fragment in the cells correlates with the degree of their drug resistance.


Subject(s)
Drug Resistance , Gene Amplification , Animals , Base Sequence , Cell Line , Cricetinae , Cricetulus , DNA/genetics , Demecolcine/toxicity , Doxorubicin/toxicity , Female , Lung , Nucleic Acid Hybridization , Ovary
12.
Cancer Res ; 43(9): 4098-101, 1983 Sep.
Article in English | MEDLINE | ID: mdl-6575863

ABSTRACT

The transplantable murine Dunn osteosarcoma has no detectable hypoxanthine:guanine phosphoribosyltransferase (EC 2.4.2.8) activity. This was established from the tumors directly and from tissue culture cell lines derived from the tumor using a variety of assays: e.g., no [3H]hypoxanthine uptake into tumor or tissue culture cells, no conversion of [3H]hypoxanthine to [3H]IMP by cell extracts from tumors or tissue culture cells, no growth of tissue culture cells in hypoxanthine:aminopterin:thymidine medium, and normal growth of these cells in 10 microM 6-mercaptopurine. Ten human osteosarcomas have been assayed, and two have no apparent hypoxanthine:guanine phosphoribosyltransferase enzyme activity. After high-dose methotrexate treatment in vivo, murine tumors could be selectively killed and normal tissues could be spared by using a rescue regimen of hypoxanthine-thymidine-allopurinol.


Subject(s)
Formates , Hypoxanthine Phosphoribosyltransferase/deficiency , Osteosarcoma/enzymology , Animals , Carbon Radioisotopes , Cell Line , Formates/metabolism , Hypoxanthine , Hypoxanthines/metabolism , Kinetics , Mice , Mice, Inbred Strains , Sarcoma, Experimental/enzymology
13.
J Clin Oncol ; 1(4): 251-4, 1983 Apr.
Article in English | MEDLINE | ID: mdl-6583319

ABSTRACT

The number and time to appearance of pulmonary metastases were evaluated in 15 patients with osteogenic sarcoma receiving adjuvant chemotherapy with high-dose methotrexate and doxorubicin (adjuvant group). The results were compared to 33 age- and sex-matched controls (control group). The adjuvant group demonstrated a reduction in the number and a delay in the appearance of the metastases. The median time to development of metastases was 17 mo in the adjuvant group and 7 mo in the control group, and the median number of metastases was 2 and 12, respectively.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Lung Neoplasms/secondary , Osteosarcoma/drug therapy , Bone Neoplasms/secondary , Combined Modality Therapy , Doxorubicin/administration & dosage , Follow-Up Studies , Humans , Lung Neoplasms/prevention & control , Methotrexate/administration & dosage , Osteosarcoma/pathology , Osteosarcoma/surgery , Time Factors
14.
J Clin Oncol ; 1(3): 208-16, 1983 Mar.
Article in English | MEDLINE | ID: mdl-6607976

ABSTRACT

Four separate groups of patients have been studied: (1) The effect of high-dose methotrexate (MTX) administration on glomerular filtration rate was determined by pre- and posttreatment inulin and creatinine clearances in nine patients. Measurements were made prior to and 24-40 hr after drug administration. Inulin and creatinine clearances both decreased a mean of 43%. No signs of systemic toxicity occurred. (2) Three other patients given high-dose courses of MTX developed MTX toxicity. Their creatinine clearance decreased an average of 61%. (3) In a separate group of five patients undergoing weekly MTX treatment, comparison of serum MTX pharmacokinetics with and without alkalinization of the urine demonstrated no significant difference in peak serum MTX levels or serum MTX decay. (4) Eight additional patients with severe renal dysfunction secondary to MTX were treated with increased doses of leucovorin and a continuous infusion of thymidine (8 g/m2/day) once renal failure was recognized. When high-dose leucovorin and thymidine were begun 48-72 hr after the MTX infusion, severe toxicity in the form of leukopenia, thrombocytopenia, diffuse mucositis, stomatitis, or skin rash was averted. We concluded the following: (1) high-dose MTX causes a subclinical decrease in glomerular filtration rate with each administration, even in nontoxic courses; (2) alkalinization of the urine with sodium bicarbonate does not alter plasma MTX decay, while volume expansion (hydration) is maintained constant; and (3) rigorous monitoring of serum creatinine and serum MTX levels 24-48 hr after MTX administration allows for the institution of rescue measures, including leucovorin and thymidine, which will abort the systemic toxicity that accompanies MTX-induced renal failure.


Subject(s)
Kidney Diseases/chemically induced , Leucovorin/administration & dosage , Methotrexate/adverse effects , Neoplasms/drug therapy , Thymidine/administration & dosage , Adolescent , Adult , Child , Creatinine/blood , Dose-Response Relationship, Drug , Drug Therapy, Combination , Glomerular Filtration Rate , Humans , Inulin , Kidney Diseases/drug therapy , Kidney Diseases/physiopathology , Kinetics , Methotrexate/administration & dosage , Methotrexate/blood , Neoplasms/physiopathology
15.
Cancer Chemother Pharmacol ; 10(1): 55-61, 1982 Dec.
Article in English | MEDLINE | ID: mdl-7160046

ABSTRACT

The pharmacokinetics and metabolism of dibutyl methotrexate (DBMTX) and gamma-monobutyl methotrexate (gamma-MBMTX) were studied in Rhesus monkeys. When a bolus IV dose of either [3H]DBMTX or [3H] gamma-MBMTX was given, the principal species in serum for up to 1 h was the monoester, with MTX accounting for less than 10% of the total radioactivity. Products other than gamma-MBMTX and MTX were formed in substantial amounts with DBMTX, but not with gamma-MBMTX. Total radioactivity recovered in the bile 5 h after [3H]DBMTX injection accounted for 32% of the administered dose, indicating high hepatic extraction for this lipophilic compound. Serum and CSF levels of unchanged gamma-MBMTX, as well as of MTX arising via esterase cleavage, were measured by HPLC after IV infusion of gamma-MBMTX (10 g/m2). Efflux of monoester from CSF was slower than disappearance from serum. However, gamma-MBMTX levels in CSF were no higher than could be attained by infusing MTX itself at the same dose rate. While CSF/serum ratios were ca. 10-fold higher for gamma-MBMTX than for MTX, this difference could be explained on the basis of the very different affinities of the two compounds for serum proteins. HPLC analysis of serum processed by methanol precipitation as opposed to ultrafiltration of the proteins showed gamma-MBMTX to be greater than 99% bound, whereas for MTX this value was 50% or less. When gamma-MBMTX and MTX levels measured after ultrafiltration were corrected for this difference in serum protein binding the total amount of the two drugs in serum became almost equivalent.


Subject(s)
Methotrexate/analogs & derivatives , Animals , Blood Proteins/metabolism , Chromatography, High Pressure Liquid , Macaca mulatta , Methotrexate/blood , Methotrexate/metabolism , Protein Binding
16.
Leuk Res ; 6(6): 775-80, 1982.
Article in English | MEDLINE | ID: mdl-6984113

ABSTRACT

Normal thymocyte and bone marrow terminal deoxynucleotidyl transferase (TdT) have distinguishing characteristics by phosphocellulose chromatography in Tris buffer: marrow TdT elutes as a single peak at 0.3 M salt, whereas thymocyte TdT separates into two forms, one at 0.3 M salt and one at 0.4 M salt. Since the majority of TdT-positive acute leukemias are anatomically bone marrow-derived, one would have predicted the presence of a bone marrow TdT-phosphocellulose chromatographic pattern in such patients. However, in 376 consecutive, untreated TdT-positive acute lymphoblastic leukemias (ALL) studied by us we have invariably encountered the two-peak thymocyte-type phosphocellulose pattern. The TdT patterns in the thymic-dependent, TdT-positive lymphoma of AKR mice, and the TdT-positive bone marrow-derived, thymic-independent Abelson virus leukemia of Balb/C mice duplicate the situation in human ALL: a thymocyte pattern is seen in both the marrow-derived and thymus-derived diseases. This chromatographic difference between leukemia-associated and normal marrow-associated TdT in both murine and human leukemia suggested that phosphocellulose-TdT patterns might be useful for monitoring residual marrow tumour cell burden in TdT-positive leukemia. This has not turned out to be the case: in eight patients studied in early relapse the blast cell TdT pattern was the single-peak 0.3 M species. Therefore, leukemic cell TdT cannot reliably be distinguished from normal marrow cell TdT. The chromatographic behaviour of TdT may be regulated by phosphorylation-dephosphorylation, the 0.3 M salt peak can be converted to the 0.4 M salt species by treatment with protein kinase and ATP, and the 0.4 M species can be converted to the 0.3 M form by exposure to alkaline phosphatase. Thus, apparently anatomic compartment-specific forms of TdT may only reflect differing cellular metabolic activity.


Subject(s)
DNA Nucleotidylexotransferase/analysis , DNA Nucleotidyltransferases/analysis , Leukemia, Lymphoid/enzymology , Lymphocytes/enzymology , Adolescent , Adult , Aged , Animals , Bone Marrow/enzymology , Child , Child, Preschool , Chromatography, Ion Exchange , Humans , Leukemia, Experimental/enzymology , Mice , Mice, Inbred AKR , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Inbred DBA , Middle Aged , T-Lymphocytes/enzymology
18.
Natl Cancer Inst Monogr ; (56): 201-6, 1981 Apr.
Article in English | MEDLINE | ID: mdl-6975438

ABSTRACT

From 1972 to 1979, high-dose methotrexate (HDMTX) and 3 adjuvant regimens were used at the Sidney Farber Cancer Institute and Children's Hospital Medical Center. In the first regiment, HDMTX was used alone; the second, HDMTX and adriamycin, and the third, weekly courses of HDMTX and combination. Actuarial disease-free survival achieved with these regimens in patient with local control of the primary lesion varied from 42 to 75% at 3 years. This compared favorably with historical control patients, of whom 50% were free of disease at 6 months and only 20% at 12 months. Among 41 patients with established pulmonary metastases, 14 were alive and free of disease from more than 4 to over 60 months. The most efficacious method of administering HDMTX was a weekly schedule which produced an overall response rate of 48% in the treatment of pulmonary metastases and primary tumor in patients previously not exposed to HDMTX. Urinary alkalinization was not a standard procedure, and investigations failed to demonstrate any significant effect of alkalinization on HDMTX pharmacokinetics.


Subject(s)
Antineoplastic Agents/administration & dosage , Bone Neoplasms/therapy , Methotrexate/administration & dosage , Osteosarcoma/therapy , Bone Neoplasms/mortality , Bone Neoplasms/pathology , Child , Doxorubicin/administration & dosage , Humans , Kinetics , Leucovorin/administration & dosage , Lung Neoplasms/secondary , Lung Neoplasms/therapy , Methotrexate/metabolism , Osteosarcoma/mortality , Osteosarcoma/pathology , Vincristine/administration & dosage
19.
Cancer Treat Rep ; 65 Suppl 1: 137-40, 1981.
Article in English | MEDLINE | ID: mdl-6976830

ABSTRACT

Thirteen patients with primary and metastatic CNS tumors have been treated with methotrexate (MTX) using three different approaches: (a) high-dose MTX with leucovorin (LV) rescue; (b) high-dose MTX with carboxypeptidase (CPDG) rescue; and (c) intraventricular administration of low doses of MTX for extended periods (concentration X time [CXT]). Eleven patients had central nervous system (CNS) lymphoma (one primary, one patient had recurrent medulloblastoma, and another patient had metastatic breast carcinoma. All 13 patients received high-dose MTX-LV rescue, while 3 patients were subsequently given MTX-CPDG. One patient received MTX by all three modalities. In patients with CNS lymphomas, complete responses (45%) and partial responses (36%) produced CNS disease-free intervals ranging from 1 to 23+ months. Survival for the complete responders has thus far ranged from 2.5 to 35 months, while the partial responders survived from 3 to 5 months. Two patients failed to respond and survived 2.5 and 3 months. Responses were obtainable with high-dose MTX-CPDG in patients resistant to MTX-LV. One patient who became sensitized to CPDG subsequently responded to MTX by intraventricular CXT administration. Thus, MTX can be effectively administered to patients with CNS tumors by several different approaches.


Subject(s)
Brain Neoplasms/drug therapy , Lymphoma/drug therapy , Methotrexate/administration & dosage , Adolescent , Adult , Aged , Brain Neoplasms/mortality , Brain Neoplasms/secondary , Breast Neoplasms/drug therapy , Carboxypeptidases/administration & dosage , Female , Humans , Injections, Intraventricular , Leucovorin/administration & dosage , Lymphoma/mortality , Lymphoma/secondary , Male , Medulloblastoma/drug therapy , Middle Aged , Time Factors
20.
Cancer Treat Rep ; 65 Suppl 1: 99-106, 1981.
Article in English | MEDLINE | ID: mdl-6948612

ABSTRACT

This communication provides a description and update of the three adjuvant regimens utilized at the Sidney Farber Cancer Institute. The disease-free survivals are: Study I--42% at 4 years; Study II--58% at 3 years; and Study III--currently 78%. In the limb salvage experience, among the evaluable patients, 6 of 12 treated with preoperative chemotherapy are disease free (median 32 months) and 12 of 14 (86%) treated without preoperative chemotherapy are disease free (median 13 months).


Subject(s)
Bone Neoplasms/drug therapy , Extremities , Methotrexate/administration & dosage , Osteosarcoma/drug therapy , Amputation, Surgical , Angiography , Bone Neoplasms/blood supply , Bone Neoplasms/surgery , Dose-Response Relationship, Drug , Drug Administration Schedule , Drug Therapy, Combination , Extremities/blood supply , Humans , Lung Neoplasms/drug therapy , Lung Neoplasms/secondary , Osteosarcoma/blood supply , Osteosarcoma/surgery , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...